Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.5% - What's Next?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) were up 11.5% during mid-day trading on Friday . The company traded as high as $0.45 and last traded at $0.42. Approximately 34,499,859 shares traded hands during trading, a decline of 67% from the average daily volume of 103,399,938 shares. The stock had previously closed at $0.38.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Sunday. They set a "hold" rating for the company.

Tonix Pharmaceuticals Trading Down 54.5 %

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market capitalization of $36.42 million, a P/E ratio of 0.00 and a beta of 2.07. The company's fifty day simple moving average is $0.30 and its 200-day simple moving average is $0.27.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.